Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Targeting opioid receptor heterodimers: strategies for screening and drug development.

Gupta A, Décaillot FM, Devi LA.

AAPS J. 2006 Mar 10;8(1):E153-9. Review.

2.

Bivalent ligands as specific pharmacological tools for G protein-coupled receptor dimers.

Berque-Bestel I, Lezoualc'h F, Jockers R.

Curr Drug Discov Technol. 2008 Dec;5(4):312-8. Review.

PMID:
19075611
3.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
4.

Opioid receptors: Structural and mechanistic insights into pharmacology and signaling.

Shang Y, Filizola M.

Eur J Pharmacol. 2015 Sep 15;763(Pt B):206-13. doi: 10.1016/j.ejphar.2015.05.012. Epub 2015 May 14. Review.

5.

Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization.

Pfeiffer M, Koch T, Schröder H, Laugsch M, Höllt V, Schulz S.

J Biol Chem. 2002 May 31;277(22):19762-72. Epub 2002 Mar 14.

6.

Opioid-receptor-heteromer-specific trafficking and pharmacology.

van Rijn RM, Whistler JL, Waldhoer M.

Curr Opin Pharmacol. 2010 Feb;10(1):73-9. doi: 10.1016/j.coph.2009.09.007. Epub 2009 Oct 19. Review.

8.

The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways.

Rovira X, Pin JP, Giraldo J.

Trends Pharmacol Sci. 2010 Jan;31(1):15-21. doi: 10.1016/j.tips.2009.10.008. Epub 2009 Dec 4. Review.

PMID:
19963287
9.

Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist.

Wang HL, Hsu CY, Huang PC, Kuo YL, Li AH, Yeh TH, Tso AS, Chen YL.

J Neurochem. 2005 Mar;92(6):1285-94.

10.
11.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
12.

Molecular biology and pharmacology of cloned opioid receptors.

Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, Yamamura HI.

FASEB J. 1995 Apr;9(7):516-25. Review.

13.

Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4.

Décaillot FM, Rozenfeld R, Gupta A, Devi LA.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):16045-50. doi: 10.1073/pnas.0804106105. Epub 2008 Oct 3.

14.

Opioids and their complicated receptor complexes.

Jordan BA, Cvejic S, Devi LA.

Neuropsychopharmacology. 2000 Oct;23(4 Suppl):S5-S18. Review.

15.

Multiple ligands in opioid research.

Ballet S, Pietsch M, Abell AD.

Protein Pept Lett. 2008;15(7):668-82. Review.

PMID:
18782061
16.

The ORL1 receptor: molecular pharmacology and signalling mechanisms.

New DC, Wong YH.

Neurosignals. 2002 Jul-Aug;11(4):197-212. Review.

PMID:
12393946
17.

Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking.

Devi LA.

Trends Pharmacol Sci. 2001 Oct;22(10):532-7. Review.

PMID:
11583811
18.

From in vivo to in vitro/in silico ADME: progress and challenges.

Van de Waterbeemd H.

Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):1-4.

PMID:
16922647
19.

Affinity-based screening techniques for enhancing lead discovery.

Comess KM, Schurdak ME.

Curr Opin Drug Discov Devel. 2004 Jul;7(4):411-6. Review.

PMID:
15338950
20.

GPCR functional selectivity has therapeutic impact.

Mailman RB.

Trends Pharmacol Sci. 2007 Aug;28(8):390-6. Epub 2007 Jul 13. Review.

Items per page

Supplemental Content

Write to the Help Desk